02:04 PM EDT, 08/12/2024 (MT Newswires) -- Lucid Diagnostics ( LUCD ) shares were up more than 4% in recent Monday trading following the company's quarterly results.

The company reported a Q2 non-GAAP loss of $0.20 per diluted share, narrowing from a loss of $0.23 a year earlier.

Three analysts polled by Capital IQ expected a loss of $0.18 per share.

Revenue for the quarter ended June 30 was $976,000, compared with $159,000 a year earlier.

Analysts surveyed by Capital IQ expected $1.2 million.

The company said it had $24.9 million in cash and cash equivalents as of June 30.

Price: 0.83, Change: +0.03, Percent Change: +4.43